Mirae Asset Global Investments Co. Ltd. Reduces Stock Holdings in HealthEquity, Inc. $HQY

Key Points

• Mirae Asset Global Investments Co. Ltd. reduced its stake in HealthEquity, Inc. by 98.9% in Q2, now holding only 279 shares valued at approximately $29,000.
• Several institutional investors have changed their positions in HealthEquity, with GAMMA Investing LLC increasing its stake by 25.9% to a total of 1,571 shares valued at $139,000.
• Analysts have set varying price targets for HealthEquity, with estimates ranging from $110.00 to $134.00 and an overall average price target of $121.31.

Mirae Asset Global Investments Co. Ltd. decreased its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 98.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 279 shares of the company's stock after selling 24,376 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in HealthEquity were worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HQY. GAMMA Investing LLC lifted its position in HealthEquity by 25.9% during the first quarter. GAMMA Investing LLC now owns 1,571 shares of the company's stock valued at $139,000 after buying an additional 323 shares during the period. SG Americas Securities LLC lifted its position in HealthEquity by 7.1% during the first quarter. SG Americas Securities LLC now owns 5,843 shares of the company's stock valued at $516,000 after buying an additional 388 shares during the period. Integrated Advisors Network LLC purchased a new position in HealthEquity during the first quarter valued at $259,000. Fifth Third Bancorp lifted its position in HealthEquity by 17.5% during the first quarter. Fifth Third Bancorp now owns 955 shares of the company's stock valued at $84,000 after buying an additional 142 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in HealthEquity by 24.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock valued at $564,000 after buying an additional 1,265 shares during the period. Hedge funds and other institutional investors own 99.55% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on HQY. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of HealthEquity in a research report on Wednesday, October 8th. Jefferies Financial Group lifted their price target on HealthEquity from $130.00 to $134.00 and gave the stock a "buy" rating in a research report on Wednesday, September 3rd. KeyCorp lowered their price target on HealthEquity from $125.00 to $120.00 and set an "overweight" rating for the company in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on HealthEquity from $125.00 to $126.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 3rd. Finally, Royal Bank Of Canada lifted their price target on HealthEquity from $109.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $121.31.

Insider Activity

In other HealthEquity news, EVP Delano Ladd sold 6,000 shares of the business's stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $94.11, for a total transaction of $564,660.00. Following the completion of the sale, the executive vice president directly owned 79,456 shares in the company, valued at $7,477,604.16. The trade was a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael Henry Fiore sold 1,781 shares of the business's stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total value of $157,102.01. Following the sale, the executive vice president owned 49,795 shares of the company's stock, valued at approximately $4,392,416.95. This represents a 3.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

HealthEquity Price Performance

NASDAQ HQY opened at $90.54 on Monday. HealthEquity, Inc. has a one year low of $74.07 and a one year high of $116.65. The stock has a 50-day moving average of $91.62 and a 200 day moving average of $93.90. The company has a market capitalization of $7.80 billion, a price-to-earnings ratio of 54.87, a PEG ratio of 1.30 and a beta of 0.47. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.23 and a current ratio of 4.23.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its quarterly earnings data on Tuesday, September 2nd. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. HealthEquity had a return on equity of 12.04% and a net margin of 11.49%.The company had revenue of $325.80 million during the quarter, compared to the consensus estimate of $320.68 million. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. On average, sell-side analysts forecast that HealthEquity, Inc. will post 2.32 EPS for the current year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.